These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21324086)

  • 21. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism.
    Oner G; Muderris II
    Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
    Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
    Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
    Brown C; Ling F; Wan J
    J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
    Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
    Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol.
    Paoletti AM; Lello S; Fratta S; Orrù M; Ranuzzi F; Sogliano C; Concas A; Biggio G; Melis GB
    Fertil Steril; 2004 Mar; 81(3):645-51. PubMed ID: 15037415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene.
    Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Cianci A
    Contraception; 2004 Mar; 69(3):237-40. PubMed ID: 14969672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the quality of life and sexual functioning of women using a 30-microg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive.
    Skrzypulec V; Drosdzol A
    Eur J Contracept Reprod Health Care; 2008 Mar; 13(1):49-57. PubMed ID: 18283600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study.
    van Lunsen RHW; Zimmerman Y; Coelingh Bennink HJT; Termeer HMM; Appels N; Fauser BCJM; Laan E
    Contraception; 2018 Jul; 98(1):56-62. PubMed ID: 29490289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
    Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I
    Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners.
    Guida M; Di Spiezio Sardo A; Bramante S; Sparice S; Acunzo G; Tommaselli GA; Di Carlo C; Pellicano M; Greco E; Nappi C
    Hum Reprod; 2005 Apr; 20(4):1100-6. PubMed ID: 15608030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women.
    Cayan F; Dilek U; Pata O; Dilek S
    J Sex Med; 2008 Jan; 5(1):132-8. PubMed ID: 17961145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
    Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
    J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J; Bardenheuer K; Heinemann K
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines.
    Coffee AL; Sulak PJ; Hill AJ; Hansen DJ; Kuehl TJ; Clark JW
    J Womens Health (Larchmt); 2014 Apr; 23(4):310-7. PubMed ID: 24450487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.